ClinicalTrials.gg
CompletedNCT01185782Updated Dec 27, 2013Results posted

SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women

A Phase 3 interventional study of Gonalef® (Follitropin alfa) and Purified pituitary gonadotropin (Fertinorm-P®) in Infertility and Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Japan. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
6th of 30
300 · median 159
Started
2007
with 2 others
Phase 3
9 of 30
1 open now
Registered
10th of 30
by date
Lead sponsor
8 of 30
Merck KGaA, Darmstadt, Germany

Among the 30 studies testing follitropin alfa in Infertility, this one is the 6th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 10th registered.

Infertility

2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 39 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory disorders who are infertile due to hypothalamic or pituitary dysfunction and have amenorrhea I or anovulatory cycles (including oligomenorrhea and polymenorrhea).

This was a phase III, multicentre, single-blind, parallel-group comparative study conducted to provide confirmatory evidence of non-inferiority of SJ-0021 versus purified gonadotropin, a comparator drug, for induction of follicle development and ovulation in infertile Japanese women and to provide further information on the safety and tolerability of SJ-0021.

Read the detailed description

Follicle stimulating hormone (FSH) is a heterodimeric glycoprotein wherein an alfa subunit and a beta subunit are noncovalently bonded. Follicle stimulating hormone is one of the key hormones regulating reproductive functions in both female and male mammals, including humans. In females, it stimulates the development of ovarian follicles, which carry oocytes, while in males it promotes spermatogenesis. Synthesis and secretion of FSH are stimulated by gonadotropin releasing hormone (GnRH), a hypothalamic peptide. Complete or partial deficiencies in FSH secretion are common causes of infertility in men and women. In women, this state is characterized by absence of ovulation or abnormal ovulation. In men, it leads to absence of or abnormally low production of spermatozoa. Administration of FSH, either alone or in combination with luteinizing hormone (LH), has been used successfully to treat these infertility problems. Until recently, only human menopausal gonadotropin (hMG), a mixture of human LH and FSH extracted from the urine of post-menopausal women, and purified FSH (u-hFSH), which could be used to reduce the LH content, had been available for treatment of infertility. In Japan, hMG and u-hFSH are still used to induce ovulation.

Purified pituitary gonadotropin, which was used as the comparator drug in this clinical trial, is a urinary gonadotropin preparation. However, it is not classified as hMG, but rather as a purified pituitary gonadotropin (u-hFSH), and is the preparation most commonly used in Japan. Since the LH content of u-hFSH is very low, it can be administered relatively safely, if adequate care is taken, to patients with polycystic ovary syndrome (PCOS). SJ-0021 is a recombinant human FSH (r-hFSH) that is produced using Chinese hamster ovary (CHO) cells as the host cells. The generic name for SJ-0021 is follitropin alfa for injection, and it is marketed overseas as GONAL-f®. It was approved in Japan in January 2006 as being effective in inducing spermatogenesis in cases of male hypogonadotropic hypogonadism (MHH).

OBJECTIVES

  • To examine the efficacy of SJ-0021 versus purified pituitary gonadotropin for ovulation induction and follicle development in subjects with amenorrhea I or anovulatory cycles, and to verify the non-inferiority of SJ-0021 versus the comparator drug
  • To assess the safety of SJ-0021

This clinical trial comprised of a pretrial observation period, a treatment period [IMP administration period], and a post-treatment assessment period. The clinical trial was scheduled in such a way that spontaneous menstruation or withdrawal bleeding induced by progesterone administration occurred within 28 days after the completion of baseline tests conducted during the pretrial observation period. A visit to the trial site was then scheduled for any day between Day 2-5 of the spontaneous menstruation or withdrawal bleeding, during which actual registration of the subject for randomization and pre-administration tests were performed. After completion of pre-administration tests, 75 IU of either SJ-0021 or purified pituitary gonadotropin that was allocated to the subject was subcutaneously administered on the same day (dosing Day 1 of treatment period), and the same daily dose was maintained for the first 7 days of the treatment period. On dosing Day 8, the mean diameter of the dominant follicle was measured; if it was \< 11 mm, the daily IMP dose was increased by 37.5 IU and this new daily dose was administered for the next 7 days. If the mean diameter of the dominant follicle was ≥ 11 mm but \< 18 mm, the same (previous) IMP dose was administered for the next 7 days. If the mean diameter of the dominant follicle had already reached 18 mm or above, administration of the IMP was terminated, and the subject moved on to the post treatment assessment period. Similarly, if the mean diameter of the dominant follicle was \< 11 mm on dosing Day 15 or Day 22, the dose was increased; if it was ≥ 11 mm but \< 18 mm, administration was continued at the same previous dose, and if it was ≥ 18 mm IMP administration was terminated. The maximum dose of IMP that can be administered was 187.5 IU/day and the maximum dosing period for the IMP was 28 days. In addition to Day 8, Day 15 and Day 22, ultrasound examination can be conducted once or twice a week during the treatment period, based on the status of growth of the dominant follicle (and on every visit once the dominant follicle has achieved a maximum diameter of 16 mm).

Examinations for the first day of the post-treatment assessment period were conducted, as appropriate, on the day when the mean diameter of the dominant follicle reached ≥ 18 mm or on the day after dosing Day 28 of the IMP. The hCG cancellation criterion (i.e. four or more ovarian follicles with a mean diameter ≥ 16 mm) was also verified at the same time. If the hCG cancellation criterion was not met, a single dose of 5000 IU of hCG was administered intramuscularly, within 24 hours of the last ultrasound examination. Mid-luteal phase tests were conducted on Day 6 ± 1 and Day 9 ± 1 of the post-treatment assessment period, and a final examination was performed on Day 28-31 of the post-treatment assessment period. If the pregnancy test (urine) conducted at this final examination was positive, a further pregnancy test (ultrasound examination) was performed on Day 35-42 of the post-treatment assessment period.

On the other hand, if the mean diameter of the dominant follicle remained \< 16 mm on the day after dosing Day 28 of the IMP, or the hCG cancellation criterion was met, hCG administration was withheld, and the examinations for the first day of the post-treatment assessment period as well as the final examination on Day 28-31 of the post-treatment assessment period were performed accordingly.

03

Conditions studied

  • Infertility
  • Ovulation Induction

Keywords

  • Infertility
  • Ovulation induction
  • Gonalef® (Follitropin alfa)
  • Purified pituitary gonadotropin (Fertinorm-P®)
  • gonadotropin
  • Reproductive technologies, assisted
  • Polycystic ovary syndrome
04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 20 to 39 years (inclusive) who hope to bear children
  • Subjects who failed to achieve ovulation or pregnancy despite 2 cycles or more of anti-estrogen therapies (clomiphene citrate, cyclofenil, etc.)
  • Subjects who exhibited withdrawal bleeding in a progesterone test (Includes spontaneous menstruation in subjects with anovulatory cycles.)
  • Subjects having a between 17.0 and 28.0 at the time of baseline tests
  • Subjects who voluntarily consented in writing to participate in the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Subjects with ovarian tumors
  • Subjects with ovarian enlargement not due to PCOS
  • Subjects with genitourinary hemorrhage of unknown cause
  • Subjects who were or may be pregnant, or who were lactating
  • Subjects with history of allergic reaction or to gonadotropin
  • Subjects with dysfunction of heart, lungs, kidneys, or cardiovascular systems of Grade 2 or higher (in compliance with the Pharmaceutical and Medical Safety Bureau Notification Yakuan No. 80 [issued 29 June 1992])
  • Subjects with serum progesterone (P4) level ≥ 5 ng/mL in baseline tests
  • Subjects with malignant tumors
  • Subjects with uterine amenorrhea
  • Subjects with elevated levels of serum gonadotropin due to premature ovarian failure (FSH ≥ 20 mIU/mL)
  • Subjects who were infertile due to known adrenal or thyroid dysfunction
  • Subjects who were diagnosed as having hyperprolactinemia
  • Subjects who had been documented or suspected of having intracranial lesions (e.g., pituitary tumors)
  • Infertile subjects involving gynecological factors other than amenorrhea I or anovulatory cycles, and for whom ovulation induction therapy was found to be
  • Subjects who had participated in another clinical study within 6 months prior to start of the IMP administration
  • Subjects who had been administered SJ-0021 in the past
  • Subjects whose participation in this clinical trial was otherwise deemed inappropriate by the investigator or sub-investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    SJ-0021 group

    Drug: Gonalef® (Follitropin alfa)

  • Active comparator
    Purified pituitary gonadotropin group

    Drug: Purified pituitary gonadotropin (Fertinorm-P®)

Interventions

  • Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.

    Also known as: Gonalef®, follitropin alfa, recombinant human follicle-stimulating hormone, r-hFSH, SJ-0021

  • Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.

    Also known as: Fertinorm-P®, purified urinary human follicle-stimulatin hormone, urofollitropin, u-hFSH

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Ovulation

    Participants were considered to have ovulated if serum progesterone (P4) level was greater than or equal to 5 nanogram (ng)/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.

    Time frame: On Day 6±1 or 9±1 days during post-treatment assessment period (Day 35-42 of post-treatment period for clinical pregnancy)]

Secondary outcomes

  1. Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter

    Time frame: Start of treatment period until Day 1 of post-treatment assessment period

  2. Time for Dominant Follicle to Achieve 18 mm in Mean Diameter

    Dosing time length was calculated as number of days from the first administration of the IMP until the mean diameter of the dominant follicle was confirmed to have reached 18 mm.

    Time frame: Start of treatment period until Day 1 of post-treatment assessment period

  3. Total Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter

    Total dose of IMP administered was defined as the cumulative dose administered from the start of treatment with IMP until the mean diameter of the dominant follicle reached 18 mm.

    Time frame: Start of treatment period until Day 1 of post-treatment assessment period

  4. Human Chorionic Gonadotropin (hCG) Cancellation Rate

    hCG cancellation criterion was defined as the presence of 4 or more ovarian follicles with a mean diameter greater than or equal to 16 mm. If the hCG cancellation criterion was met, the administration of hCG was withheld. Otherwise, a single intramuscular dose of hCG 5000 IU (Japanese Pharmacopoeia- JP) was administered within 24 hours of the last ultrasound examination.

    Time frame: Day 1 of post-treatment assessment period

  5. Single Follicle Maturation Rate

    Single follicle maturation was defined as the presence of the dominant follicle with a mean diameter of 18 mm or greater without concurrent presence of other follicles of 14 mm or larger in diameter.

    Time frame: Start of treatment period until Day 1 of post-treatment assessment period

  6. Biochemical Pregnancy Rate

    Biochemical pregnancy was defined as a positive pregnancy test (urinary beta-hCG test) on Day 28-31 of the post-treatment assessment period

    Time frame: Day 28-31 of post-treatment assessment period

  7. Clinical Pregnancy Rate

    Clinical pregnancy was defined as existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.

    Time frame: Day 35-42 of post-treatment assessment period

  8. Ovulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy

    For this secondary endpoint, participants were considered to have ovulated if serum P4 level was more than or equal to 10 ng/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.

    Time frame: On Day 6±1 or 9±1 during post-treatment assessment period

  9. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

    AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the IMP. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. Participants who discontinued from the study due to AE were also recorded.

    Time frame: Pretrial observation period to post-treatment assessment period (Days 35-42)

  10. Number of Participants With OHSS

    OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

    Time frame: Start of treatment period to post-treatment assessment period (Day 35-42)

07

Results

Posted Feb 24, 2012

Participant flow

Participants were recruited in 21 study centers in Japan from 15 February 2007 to 25 December 2007.

Participant flow — Overall Study
MilestoneSJ-0021u-hFSH
Started129136
Treated129132
Completed123125
Not completed611
Withdrew: Adverse event01
Withdrew: Protocol violation10
Withdrew: Poor response to treatment31
Withdrew: Other25
Withdrew: Randomized but not treated04

Outcome measures

PrimaryPercentage of Participants With Ovulation

Participants were considered to have ovulated if serum progesterone (P4) level was greater than or equal to 5 nanogram (ng)/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.

Time frame:
On Day 6±1 or 9±1 days during post-treatment assessment period (Day 35-42 of post-treatment period for clinical pregnancy)]
Reported as:
Number · percentage of participants
Percentage of Participants With Ovulation
percentage of participantsSJ-0021u-hFSH
Percentage of Participants With Ovulation79.182.6
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · Delta: -3.51 · 95% CI -13.05 to 6.04
SecondaryNumber of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter
Time frame:
Start of treatment period until Day 1 of post-treatment assessment period
Reported as:
Number · participants
Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter
participantsSJ-0021u-hFSH
Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter117125
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · p = 0.214
SecondaryTime for Dominant Follicle to Achieve 18 mm in Mean Diameter

Dosing time length was calculated as number of days from the first administration of the IMP until the mean diameter of the dominant follicle was confirmed to have reached 18 mm.

Time frame:
Start of treatment period until Day 1 of post-treatment assessment period
Reported as:
Mean · days
Time for Dominant Follicle to Achieve 18 mm in Mean Diameter
daysSJ-0021u-hFSH
Time for Dominant Follicle to Achieve 18 mm in Mean Diameter13.1 ± 5.112.1 ± 4.2
Statistical analysis
  • SJ-0021 vs u-hFSH · t-test, 2 sided · p = 0.087
SecondaryTotal Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter

Total dose of IMP administered was defined as the cumulative dose administered from the start of treatment with IMP until the mean diameter of the dominant follicle reached 18 mm.

Time frame:
Start of treatment period until Day 1 of post-treatment assessment period
Reported as:
Mean · IU
Total Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter
IUSJ-0021u-hFSH
Total Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter959.29 ± 533.32845.70 ± 432.88
Statistical analysis
  • SJ-0021 vs u-hFSH · t-test, 2 sided · p = 0.069
SecondaryHuman Chorionic Gonadotropin (hCG) Cancellation Rate

hCG cancellation criterion was defined as the presence of 4 or more ovarian follicles with a mean diameter greater than or equal to 16 mm. If the hCG cancellation criterion was met, the administration of hCG was withheld. Otherwise, a single intramuscular dose of hCG 5000 IU (Japanese Pharmacopoeia- JP) was administered within 24 hours of the last ultrasound examination.

Time frame:
Day 1 of post-treatment assessment period
Reported as:
Number · percent hCG cancellation
Human Chorionic Gonadotropin (hCG) Cancellation Rate
percent hCG cancellationSJ-0021u-hFSH
Human Chorionic Gonadotropin (hCG) Cancellation Rate7.07.6
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · p = 0.852
SecondarySingle Follicle Maturation Rate

Single follicle maturation was defined as the presence of the dominant follicle with a mean diameter of 18 mm or greater without concurrent presence of other follicles of 14 mm or larger in diameter.

Time frame:
Start of treatment period until Day 1 of post-treatment assessment period
Reported as:
Number · percent single follicle maturation
Single Follicle Maturation Rate
percent single follicle maturationSJ-0021u-hFSH
Single Follicle Maturation Rate33.343.2
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · p = 0.102
SecondaryBiochemical Pregnancy Rate

Biochemical pregnancy was defined as a positive pregnancy test (urinary beta-hCG test) on Day 28-31 of the post-treatment assessment period

Time frame:
Day 28-31 of post-treatment assessment period
Reported as:
Number · percent biochemical pregnancy
Biochemical Pregnancy Rate
percent biochemical pregnancySJ-0021u-hFSH
Biochemical Pregnancy Rate17.815.2
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · p = 0.560
SecondaryClinical Pregnancy Rate

Clinical pregnancy was defined as existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.

Time frame:
Day 35-42 of post-treatment assessment period
Reported as:
Number · percent clinical pregnancy
Clinical Pregnancy Rate
percent clinical pregnancySJ-0021u-hFSH
Clinical Pregnancy Rate17.114.4
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · p = 0.555
SecondaryOvulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy

For this secondary endpoint, participants were considered to have ovulated if serum P4 level was more than or equal to 10 ng/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.

Time frame:
On Day 6±1 or 9±1 during post-treatment assessment period
Reported as:
Number · percent ovulation
Ovulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy
percent ovulationSJ-0021u-hFSH
Ovulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy71.375.8
Statistical analysis
  • SJ-0021 vs u-hFSH · Chi-squared · p = 0.416
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the IMP. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. Participants who discontinued from the study due to AE were also recorded.

Time frame:
Pretrial observation period to post-treatment assessment period (Days 35-42)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
participantsSJ-0021u-hFSH
TEAEs6966
SAEs11
Discontinuation due to AEs01
SecondaryNumber of Participants With OHSS

OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Time frame:
Start of treatment period to post-treatment assessment period (Day 35-42)
Reported as:
Number · participants
Number of Participants With OHSS
participantsSJ-0021u-hFSH
Number of Participants With OHSS105

Adverse events

Collected over AEs were collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the final post-treatment examination, on Day 35-42 of the post-treatment assessment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SJ-0021—1/129 (0.8%)36/129 (27.9%)
u-hFSH—1/132 (0.8%)40/132 (30.3%)
Most frequent serious events
Most frequent serious events
EventSJ-0021u-hFSH
Ovarian hyperstimulation syndromeReproductive system and breast disorders1/1291/132
Most frequent other events
Most frequent other events
EventSJ-0021u-hFSH
Abdominal pain lowerGastrointestinal disorders6/12914/132
NasopharyngitisInfections and infestations10/12911/132
Abdominal distensionGastrointestinal disorders9/1297/132
Ovarian hyperstimulation syndromeReproductive system and breast disorders9/1294/132
HeadacheNervous system disorders6/1298/132
AscitesGastrointestinal disorders4/1297/132

Baseline characteristics

Age, Continuous
Age, Continuous(years)SJ-0021u-hFSHTotal
Mean31.6 ± 3.831.6 ± 3.831.6 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)SJ-0021u-hFSHTotal
Female129132261
Male000
Previous episodes of Ovarian hyperstimulation syndrome (OHSS)
Previous episodes of Ovarian hyperstimulation syndrome (OHSS)(participants)SJ-0021u-hFSHTotal
0116119235
191019
2235
3101
4101
08

Study locations

1 site
  • The University of Tokyo Hospital
    Tokyo, Japan
09

References and documents

Publications

  • Taketani Y, Kelly E, Yoshimura Y, Hoshiai H, Irahara M, Mizunuma H, Saito H, Andoh K, Yanaihara T. Recombinant follicle-stimulating hormone (follitropin alfa) versus purified urinary follicle-stimulating hormone in a low-dose step-up regimen to induce ovulation in Japanese women with anti-estrogen-ineffective oligo- or anovulatory infertility: results of a single-blind Phase III study. Reprod Med Biol. 2010 Feb 23;9(2):99-106. doi: 10.1007/s12522-010-0046-5. eCollection 2010 Jun. PubMed 29699333 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2010
First posted
Aug 20, 2010
Start
Feb 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Feb 24, 2012
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01185782
Collaborators
Merck Serono Co., Ltd., Japan
Responsible party
Sponsor
First posted
Aug 20, 2010
Start date
Feb 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Feb 24, 2012
Last update
Dec 27, 2013

Study contacts

Kimitoshi Takemura
study director · Merck Serono Co., Ltd., Japan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion